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A well-controlled clinical trial previously demonstrated the efﬁcacy of a novel softgel
dietary supplement providing 1.8 g/day esteriﬁed plant sterols and stanols, as part of the
National Cholesterol Education Program Therapeutic Lifestyle Changes diet, to improve
the fasting lipid proﬁle of men and women with primary hypercholesterolemia (fasting
low-density lipoprotein [LDL] cholesterol 130 and <220 mg/dL [3.37 and <5.70
mmol/L]). The purpose of this randomized, double blind, placebo-controlled crossover
study (conducted July 2011 to January 2012) was to support these previous ﬁndings in
a similar, but independent, sample with a different lead investigator and research site.
Repeated measures analysis of covariance was used to compare outcomes for sterol/
stanol and placebo treatment conditions using the baseline value as a covariate. Forty-
nine subjects were screened and 30 (8 men and 22 women) were randomized to treat-
ment (all completed the trial). Baseline (meanstandard error of the mean) plasma lipid
concentrations were: total cholesterol 236.64.2 mg/dL (6.110.11 mmol/L), high-density
lipoprotein (HDL) cholesterol 56.83.0 mg/dL (1.470.08 mmol/L), LDL cholesterol
151.63.3 mg/dL (3.920.09 mmol/L), non-HDL cholesterol 179.74.6 mg/dL
(4.640.12 mmol/L), and triglycerides 144.514.3 mg/dL (1.630.16 mmol/L). Mean
placebo-adjusted reductions in plasma lipid levels were signiﬁcant (P<0.01) for LDL
cholesterol (e4.3%), non-HDL cholesterol (e4.1%), and total cholesterol (e3.5%), but not
for triglycerides or HDL cholesterol. These results support the efﬁcacy of 1.8 g/day
esteriﬁed plant sterols/stanols in softgel capsules, administered as an adjunct to the
National Cholesterol Education Program Therapeutic Lifestyle Changes diet, to augment
reductions in atherogenic lipid levels in individuals with hypercholesterolemia.
J Acad Nutr Diet. 2014;114:244-249.E
LEVATED TOTAL CHOLESTEROL, LOW-DENSITY
lipoprotein (LDL) cholesterol, and nonehigh-density
lipoprotein (non-HDL) cholesterol are risk factors for
coronary disease that are modiﬁable with dietary
intervention. A large body of evidence supports increasing
daily consumption of plant sterols and stanols as an effective
adjunct to the National Cholesterol Education Program
(NCEP) Therapeutic Lifestyle Changes (TLC) diet to lower
circulating cholesterol concentrations.1-4 Plant sterols and
stanols are commercially available in food products5-10 anddietary supplements in tablet or capsule form11-15 in amounts
sufﬁcient (1 to 3 g/day) to lower blood cholesterol levels.
A previous randomized, placebo-controlled clinical trial15
demonstrated the efﬁcacy of a novel softgel dietary supple-
ment providing 1.8 g/day esteriﬁed plant sterols/stanols,
incorporated into the NCEP TLC diet, to improve the lipid
proﬁle of men and women with primary hypercholesterole-
mia. Although the results from that study were promising,
reproducible clinical data are particularly useful for guiding
health care professionals in making lifestyle recommenda-
tions to their patients.16 Thus, the objective of our trial was to
support the results from a prior placebo-controlled, ran-
domized clinical trial15 showing that plant sterol and stanol
esters delivered in a softgel capsule would lower plasma
levels of cholesterol in atherogenic lipoprotein fractions.ª 2014 by the Academy of Nutrition and Dietetics.
RESEARCHMETHODS
Study Design
Our randomized, double-blind, placebo-controlled crossover
study utilized the same design and sterol/stanol ester softgel
capsule as a previous trial15 conducted at other research sites
with a different principal investigator. Brieﬂy, participants
completed a 5-week lead-in period during which they
consumed the weight maintenance version of the NCEP TLC
diet for 5 weeks along with placebo softgel capsules (single
blind) for at least 2 weeks (there was an unexpected delay in
the delivery of the placebo to the research clinic, resulting in
some participants not receiving the placebo for the full lead-
in period). The lead-in period was followed by two 6-week
double-blind treatment periods: four softgel capsules
providing a total of 1.8 g/day esteriﬁed plant sterols/stanols
(w2.9 g/day sterol/stanol ester) or four placebo softgel cap-
sules. Participants completed three lead-in visits (Weeks e5,
e1, and 0) and four treatment visits (Weeks 5, 6, 11, and 12).
No washout period was employed because previous research
has shown that 6 weeks should be sufﬁcient to establish a
new steady state for plasma lipid concentrations.17 This study
was conducted from July 2011 to January 2012 by National
Clinical Research, Inc, and data management/analysis was
conducted by Biofortis Clinical Research according to Good
Clinical Practice Guidelines, the Declaration of Helsinki
(2000), and the US Code of Federal Regulations. The Schulman
Associates Institutional Review Board approved this study and
all participants signed a written informed consent form.
Participants
Men and women with hypercholesterolemia (fasting LDL
cholesterol level 130 mg/dL [3.4 mmol/L] and <220 mg/dL
[5.7 mmol/L]), aged 21 to 79 years, and in good general health
were eligible to participate. Exclusion criteria have been
described previously.15
Study Products and Diet Instruction
The active softgel capsules contained 0.45 g sterol/stanol
(Reducol, Forbes Medi-Tech, Inc) per capsule (81% plant ste-
rols [predominantly sitosterol] and 19% plant stanols [pre-
dominantly sitostanol]). The sterol/stanol and placebo softgel
capsules were provided by Pharmavite, LLC. Participants were
instructed to take four softgel capsules (two with each of two
main meals) at consistent times each day, and to swallow the
capsules whole with water or another beverage. All unused
study product was returned to the research site where it was
counted, and compliance was calculated based on the dif-
ference between the number of capsules dispensed and those
returned accompanied by subject query to verify that all of
the capsules not returned were consumed.
Participants were instructed to follow a weight mainte-
nance version of the NCEP TLC diet throughout the study
(including the 5-week lead-in period) and handouts were
provided to reinforce diet instructions.4,18 Participants
were also instructed to avoid consuming foods or supplement
products containing added sterols or stanols. To evaluate
dietary compliance, daily energy and macro/micronutrient
intakes were calculated (Food Processor SQL software, version
10.9, 2011, ESHA Research) from 3-day diet records (2 week-
days and 1 weekend day) completed during the week just
before randomization (start of double-blind treatment) andFebruary 2014 Volume 114 Number 2during the ﬁnal week of each treatment period. In addition,
participants were instructed to maintain habitual physical
activity patterns throughout the study and were queried
about changes in physical activity at each visit.Laboratory Measurements
Fasting (9 to 15 hours) blood samples were collected in
duplicate at baseline (Weeks e1 and 0) and at the end of
each treatment period (Weeks 5 and 6, Weeks 11 and 12).
Routine clinical laboratory measurements were conducted
as described previously.15 Lipoprotein lipid assessments
included total cholesterol, LDL cholesterol, HDL cholesterol,
non-HDL cholesterol (calculated as total cholesteroleHDL
cholesterol), triglycerides, and the total cholesterol to HDL
cholesterol ratio. LDL cholesterol concentration in milli-
grams per deciliter was calculated according to the Friede-
wald equation: LDL cholesterol¼Total cholesteroleHDL
cholesteroletriglycerides/5.18Statistical Analyses
SAS version 9.2 (2002-2008, SAS Institute Inc) was used in
the conduct of all statistical analyses. The primary outcome
was the percent change from baseline in LDL cholesterol and
secondary outcomes were other parameters of the lipopro-
tein proﬁle. A sample of 28 participants was expected to
provide 80% power to detect an effect size of 0.44 standard
deviations for the difference between treatments in LDL
cholesterol response, using a two-sided a¼.05. Assuming
a pooled standard deviation of 9% for the percent change
from baseline in LDL cholesterol, based on results from pre-
vious trials,13,15,17 this would translate into a 4% difference
between treatments in response. Because the standard de-
viations for responses of other lipoprotein cholesterol values
(secondary outcomes) have generally been observed to be
similar to that for LDL cholesterol, the power to detect
changes in these would have been approximately the same as
for the primary outcome. Because triglyceride response
typically has a larger standard deviation (w25%), the study
had roughly 80% power to detect a difference of 11% between
treatments in triglyceride level response.13,15,17
Nonpaired t tests and Fisher’s exact test were used to
compare baseline characteristics for participants in the two
treatment sequences. Repeated measures analysis of covari-
ance was used to compare changes (dietary variables) or
percent changes (lipoprotein lipid variables) in continuous
variables for the sterol/stanol and placebo treatment condi-
tions, with baseline value as a covariate in each model. Values
for baseline and end of treatment were calculated as the
average from two samples collected at weeks e1 and 0 for
baseline, Weeks 5 and 6 for the end of Treatment 1, and
Weeks 11 and 12 for the end of Treatment 2. Initial models
each included participant as a random effect and terms for
treatment condition, sequence, and treatment by sequence
interactions. If an interaction term was not statistically sig-
niﬁcant (P>0.05), it was dropped from the ﬁnal model.
No material differences in responses by treatment sequence
were present that would bring into question the appropri-
ateness of pooling data from the two sequence groups. Evi-
dence of non-normality was present in model residuals for
HDL cholesterol (Shaprio-Wilk P<0.01)19; therefore, rankJOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS 245
RESEARCHtransformations were employed in the ﬁnal models for this
variable.20
Results for continuous variables are presented as
meanstandard error of the mean, including HDL choles-
terol because mean and median values were not materially
different. Frequencies of adverse events are presented as
numbers and percent of subjects experiencing each type
of event and comparisons between treatment conditions
were assessed using McNemar’s test.
RESULTS AND DISCUSSION
Forty-nine individuals were screened and 30 (8 men and 22
women) were randomized (placebo followed by sterol/stanol
n¼14; sterol/stanol followed by placebo n¼16); all 30 par-
ticipants completed the study. The primary reason for screen
failure was LDL cholesterol outside of the range required for
qualiﬁcation. All participants completed both treatment
phases and were included in the analyses. Demographic and
baseline characteristics of participants are presented in
Table 1. No statistically signiﬁcant differences were observed
between treatment sequence groups for baseline character-
istics. As shown in Table 2, signiﬁcant reductions wereTable 1. Subject characteristics at baseline in a study to
demonstrate the efﬁcacy of a novel softgel dietary
supplement providing 1.8 g/d esteriﬁed plant sterols and
stanols, as part of the National Cholesterol Education
Program Therapeutic Lifestyle Changes diet (N¼30)a
Characteristic Result
 n (%)!
Men 8 (27)
Women 22 (73)
Race/ethnicity
Non-Hispanic white 24 (80)
Asian or Paciﬁc Islander 1 (3)
Black/African American 5 (17)
Smoking status
Nonsmoker 20 (67)
Current smoker 4 (13)
Past smoker 6 (20)
meanstandard error of the mean
Age (y) 58.71.5
Weight (kg) 73.42.6
Body mass index 26.70.9
Systolic blood pressure
(mm Hg)
127.62.5
Diastolic blood pressure
(mm Hg)
77.11.6
Fasting glucose (mg/dL)b 96.31.7
aResults for both treatment sequences were pooled and values shown are for the ef-
ﬁcacy evaluable analysis sample.
bTo convert mg/dL glucose to mmol/L, multiply mg/dL by 0.0555. To convert mmol/L
glucose to mg/dL, multiply mmol/L by 18. Glucose of 70 mg/dL¼3.89 mmol/L.
246 JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICSobserved in atherogenic plasma lipid levels in the sterol/
stanol condition (LDL cholesterol e4.3%, non-HDL cholesterol
e4.1%, total cholesterol e3.5%) compared with placebo. Tri-
glycerides, HDL cholesterol, and total cholesterol/HDL
cholesterol level responses were not signiﬁcantly different
between treatment conditions.
These results support similar, statistically signiﬁcant ﬁnd-
ings from a prior study15 that was conducted at two research
clinics in Indiana and Illinois (Biofortis-Provident Clinical
Research), independent of the current study site (National
Clinical Research in Richmond, VA), that used the same
design, methods, and formulation of the sterol/stanol sup-
plement. In that study, statistically signiﬁcant placebo-
adjusted reductions in atherogenic lipid levels (e9.2% for
LDL cholesterol, e9.0% for non-HDL cholesterol, and e7.4% for
total cholesterol) were observed in a similar sample of adults
with hypercholesterolemia. Although the directions of the
changes observed in the two studies were the same, the
magnitudes of the reductions in LDL cholesterol, non-HDL
cholesterol, and total cholesterol in our study were some-
what smaller than those observed in the previous trial. The
authors view random variation as the most likely explanation
for the differences in responses, because the study protocols
and the active and placebo test products employed were
essentially identical. Our validation of the earlier study, in
conjunction with the published literature, provides support
for health care professionals to recommend the option of a
sterol/stanol supplement as an adjunct to the NCEP TLC diet
for the management of hypercholesterolemia.
The dietary supplement used in our trial and the previous
trial15 was composed of a blend of plant sterols and stanols
previously shown to lower LDL cholesterol levels when
administered in food forms such as margarine6 and choco-
late.5 Indeed, the cholesterol-lowering properties of plant
sterols/stanols in fortiﬁed food forms have been extensively
documented,1-3 but relatively few investigators have studied
the efﬁcacy of plant sterols/stanols administered in tablets or
capsules. It is important to recognize that fortiﬁed foods
containing plant sterols/stanols may be challenging for some
individuals to incorporate into a cholesterol-lowering diet on
a consistent basis. Some individuals may ﬁnd it easier to
incorporate a dietary supplement into their daily regimen.
Compliance was high in this trial as it was in the previous
study,15 with 94.3%1.2% and 96.2%1.1% of expected doses
consumed during the sterol/stanol and placebo treatment
periods, respectively (P¼0.223). In addition, all randomized
participants completed both treatment periods.
It is unlikely that the beneﬁcial changes in the atherogenic
lipid proﬁle observed with sterol/stanol supplementation
occurred due to changes in background diet because there
were no signiﬁcant changes from baseline (after the diet
lead-in) during sterol/stanol and placebo treatments for
percentages of intake from saturated fatty acids (10.8%0.6%
vs 11.2%0.8% and 10.9%0.4%; P¼0.470), polyunsaturated
fatty acids (4.1%0.3% vs 3.7%0.3% and 4.4%0.4%; P¼0.105),
monounsaturated fatty acids (7.9%0.7% vs 7.8%0.6% and
8.6%0.7%; P¼0.304), cholesterol (220.719.9 mg/day vs
252.020.5 mg/day, and 223.720.1 mg/day; P¼0.274), and
dietary ﬁber (16.41.2 g/day vs 16.21.5 g/day and 16.51.4
mg/day; P¼0.619). There were also no signiﬁcant changes
from baseline during sterol/stanol and placebo treatments for
total energy intake; percentages of intake from carbohydrate,February 2014 Volume 114 Number 2
Table 2. Fasting lipid levels at baseline and end of treatment, alongwith percent changes frombaseline and differences in responses
between treatments, in a study to demonstrate the efﬁcacy of a novel softgel dietary supplement providing 1.8 g/d esteriﬁed plant
sterols and stanols, as part of the National Cholesterol Education Program Therapeutic Lifestyle Changes dieta
Parameter
Baseline,
(mg/dL)bc
End of Treatment,
Control (mg/dL)cd
End of
Treatment,
Sterol/Stanol
(mg/dL)cd
Control,
%De
Sterol/
Stanol,
%De
% Difference
in Response
(mean)f P value
 meanstandard error of the mean!
LDLg cholesterol 151.63.3 150.54.8 143.94.5 e1.11.9 e5.41.8 e4.3 0.008
Non-HDLh cholesterol 179.74.6 177.15.4 169.85.4 e1.51.8 e5.71.6 e4.1 0.006
Total cholesterol 236.64.2 236.05.5 227.54.9 e0.31.5 e3.81.3 e3.5 0.003
HDL cholesterol 56.83.0 58.93.2 57.73.1 4.42.3 2.11.7 e2.3 0.206
Triglycerides 144.514.3 133.313.2 130.011.3 e3.04.2 e6.23.2 e3.2 0.397
Total cholesterol/HDL
cholesterol
4.50.2 4.30.2 4.20.2 e3.51.9 e5.21.5 e1.7 0.291
aResults for both treatment sequences were pooled (N¼30, efﬁcacy evaluable sample). Adjusting for differences in dietary intake did not signiﬁcantly alter results.
bBaseline¼Average of values at weeks e1 and 0.
cTo convert mg/dL cholesterol to mmol/L multiply mg/dL by 0.0259. To convert mmol/L cholesterol to mg/dL, multiply mmol/L by 38.7. Cholesterol of 200 mg/dL¼5.17 mmol/L. To
convert mg/dL triglycerides to mmol/L, multiply mg/dL by 0.0113. To convert mmol/L triglycerides to mg/dL, multiply mmol/L by 88.6. Triglycerides of 160 mg/dL¼1.8 mmol/L.
dEnd of Treatment¼Average of values at the ﬁnal 2 weeks of each treatment period (Weeks 5 and 6, and Weeks 11 and 12).
e% D¼Percentage change from baseline to end of each treatment period (average of values at Weeks 5 and 6, and Weeks 11 and 12).
f% Difference in Response¼Active % changeeControl % change.
gLDL¼low-density lipoprotein.
hHDL¼high-density lipoprotein.
RESEARCHprotein, or total fat; and intake of soluble ﬁber (data not
shown). The intake of saturated fat and cholesterol, on
average, did not reach the targets of the NCEP TLC diet of <7%
of energy from saturated fat and <200 mg/day cholesterol,
but participants did follow a diet that is lower in these dietary
components than a typical American diet. This reﬂects what
likely occurs in clinical practice, because free-living people
given dietary counseling are often unable to attain the rela-
tively stringent TLC diet recommendations.21 Also, because
reported dietary intakes did not differ between treatment
periods, this is unlikely to have affected the comparisons of
lipoprotein levels between treatment periods.
There was an increase in mean dietary cholesterol intake
during the sterol/stanol treatment period (w14% increase
relative to baseline); however, it should be noted that the
standard deviation around themean cholesterol intake during
the sterol/stanol treatment period was high (w115 mg) and,
thus, this increase cannot be reliably separated from chance.
Using the Hegsted equation22 to estimate the effect of a
31 mg/day increase in dietary cholesterol indicates that the
predicted effect on total cholesterol would be w1.2 mg/dL
(0.03 mmol/L) and, with the assumption that the contribution
to LDL cholesterol would be two thirds of this value, a differ-
ence of w0.8 mg/dL (0.02 mmol/L) in LDL cholesterol. Given
the baseline LDL cholesterol concentration of 151.6 mg/dL
(3.92 mmol/L), this translates into an increase ofw0.5% in LDL
cholesterol during the sterol/stanol condition potentially
contributed by the increase in dietary cholesterol, which
could have partially offset the LDL cholesterol reduction pro-
duced by the sterol/stanol supplement. Sensitivity analyses
that adjusted for the predicted differences in circulating LDLFebruary 2014 Volume 114 Number 2cholesterol concentration attributable to differences in dietary
fatty acid and cholesterol intakes did not suggest signiﬁcant
confounding by dietary differences between baseline and the
two treatment periods (data not shown).
There were no signiﬁcant changes from baseline in mean
body weight (<0.1 kg) or systolic and diastolic blood pres-
sures (<3 mm Hg) during either treatment period. No sig-
niﬁcant differences in adverse events were noted between
treatment conditions. Adverse events assessed at each clinic
visit after randomization were reported by four participants
(13.3%) during the sterol/stanol treatment (weight gain n¼1
and upper respiratory tract infection n¼3), and four partici-
pants (13.3%) during the placebo treatment (upper respira-
tory tract infections n¼2, urinary tract infection n¼1, and
eczema n¼1). The study physicians classiﬁed all adverse
events as mild or moderate in severity and not related or
unlikely to be related to the study products. No severe
adverse clinical effects associated with the consumption of
the study products were reported.
A small segment of the general population (one patient in
1 million) is homozygous for a genetic disorder (beta sito-
sterolemia), which occurs due to the absence or dysfunction
of two adenosine triphosphate-binding cassette (ABC)
transporters (ABCG5 and ABCG8) that facilitate the transport
of sterols, including plant sterols, from the enterocytes into
the intestinal lumen. This results in overabsorption of plant
sterols with resulting high blood levels that may damage
the arterial wall, enhancing risk for the development of
atherosclerosis.23 A recent meta-analysis24 failed to ﬁnd any
evidence of an association between blood levels of plant
sterols and increased risk of cardiovascular disease with moreJOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS 247
RESEARCHmodest levels of plant sterols, as might be observed in those
consuming diets high in plant sterols or taking dietary
supplements.
Some investigators have observed reductions in serum
carotenoid levels with sterol or stanol consumption10,25-27;
however, reduced serum carotenoids can be counteracted
with increased consumption of carotene-rich foods.17 This
premise was tested in a study of 46 participants with hy-
percholesterolemia who were instructed to consume
margarine containing 2.5 g/day plant sterols or stanols and
ﬁve or more servings of fruits and vegetables, of which one or
more servings were to include carotenoid-rich foods (eg,
carrots, sweet potatoes, pumpkins, tomatoes, apricots,
spinach, or broccoli).8 Results indicated a signiﬁcant decrease
in LDL cholesterol and a signiﬁcant increase in plasma beta
carotene concentrations. Nevertheless, the potential for
reduced carotenoid bioavailability resulting from sterol/sta-
nol consumption is a valid concern, and additional research is
needed to further clarify the magnitude of this effect with
different formulations of sterol/stanol-containing supple-
ments or foods, as well as potential clinical signiﬁcance of
such reductions.
Our study does have some limitations. The 6-week
treatment period with the sterol/stanol product focused
on relatively short-term changes in surrogate markers of
cardiovascular disease. Although short-term reductions
in cardiovascular disease risk factors appear favorable,
it remains to be determined whether continued long-
term consumption of the sterol/stanol product would
ultimately reduce major cardiovascular disease outcomes
(eg, myocardial infarction). In addition, although study entry
criteria were based on the presence of hypercholesterolemia
and did not prespecify a ﬁxed ratio of women to men,
women accounted for 73% of the study sample. Post hoc
analyses of pooled results from our trial and the previous
trial15 do not indicate a treatment by sex interaction in
response. Moreover, results from prior studies of sterols and
stanols have not indicated a treatment by sex interaction in
responses. Thus, we believe that the results herein should be
generalizable to both sexes.
Our results support previous ﬁndings that a novel sterol/
stanol softgel dietary supplement lowers atherogenic lipo-
protein levels. This is important because coronary event risk
may be reduced by w3% for each 1% lower level of LDL
cholesterol if the reduced LDL cholesterol level is main-
tained over decades, which is larger than the coronary event
risk reduction observed in clinical trials of cholesterol-
lowering drug therapies over periods of 5 to 6 years (w1%
risk reduction for each 1% reduction in LDL cholesterol).28-30
Future research studies with focus on outcome trials will
provide greater understanding of the beneﬁts of phytos-
terols for dietary management of cardiovascular disease risk
long term.CONCLUSIONS
The results of our trial support those of a previous study
demonstrating cholesterol-lowering effects of the ingestion
of 1.8 g/day esteriﬁed plant sterol and stanols given as four
dietary supplement softgel capsules (two capsules with each
of two main meals).28 For the practicing health care profes-
sional, these results provide further support for the use of248 JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICSplant sterols/stanols as an adjunct to the NCEP TLC diet. This
supplement may be particularly useful for those clients or
individuals who desire the ﬂexibility of a dietary supplement
due to the ease of incorporation into a cholesterol-lowering
dietary regimen, and the consistency of delivering a sufﬁ-
cient dose to affect blood cholesterol levels.References
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